As shown in Figure 4a, a significant dose-dependent increase in sensitivity to HCQ was observed in AML CD34+ compared with CD34+ cells isolated from healthy controls (20 μM HCQ, 23.0±3.1% versus 42.5±6.6% surviving cells, respectively, P<0.05). This evidence concerns the gene CD34 and acute myeloid leukemia.